Mirum Pharmaceuticals, Inc. Gain (Loss) on Extinguishment of Debt
Mirum Pharmaceuticals, Inc. (MIRM) reported Gain (Loss) on Extinguishment of Debt of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-02-25
- Mirum Pharmaceuticals, Inc. gain (loss) on extinguishment of debt for the quarter ending 2024-12-31 was $0.00.
- Mirum Pharmaceuticals, Inc. gain (loss) on extinguishment of debt for the quarter ending 2024-09-30 was $0.00.
- Mirum Pharmaceuticals, Inc. gain (loss) on extinguishment of debt for the quarter ending 2024-06-30 was $0.00.
- Mirum Pharmaceuticals, Inc. gain (loss) on extinguishment of debt for the quarter ending 2023-12-31 was $0.00.
- Mirum Pharmaceuticals, Inc. gain (loss) on extinguishment of debt for fiscal 2025 was $0.00.
- Mirum Pharmaceuticals, Inc. gain (loss) on extinguishment of debt for fiscal 2024 was $0.00.
- Mirum Pharmaceuticals, Inc. gain (loss) on extinguishment of debt for fiscal 2023 was -$49.08M.
- Mirum Pharmaceuticals, Inc. gain (loss) on extinguishment of debt for fiscal 2022 was $0.00.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-25 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | -$49.08M derived: sum of 3 quarters · filed 2026-02-25 | -$49.08M 10-K · filed 2026-02-25 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 | -$49.08M derived: sum of 2 quarters · filed 2024-11-12 | -$49.08M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$49.08M 10-Q · filed 2024-08-07 | -$49.08M 10-Q · filed 2024-08-07 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | $0.00 10-K · filed 2025-02-26 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-02 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-07 | $0.00 10-Q · filed 2023-08-07 | ||
| 2021-12-31 | $0.00 10-K · filed 2024-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |